Call for Abstract

World Conference on Immuno, Tumor Oncology & Drug Discovery 2019 , will be organized around the theme “Empowering Next Generation Targeted Immunotherapies

Mail Us at: [email protected]

Immuno Oncology 2019 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Immuno Oncology 2019

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

The system is that the body’s natural weaponry. It is a group of organs, cells and special molecules that facilitate defend you from infections, cancer and alternative diseases. Immuno-oncology therapies activate our system, creating it able to acknowledge cancer cells and destroy them. Breast cancer is one among the most important cancer sorts that new immune-based cancer treatments square measure presently in development. Lung cancer surgery carries risks, as well as haemorrhage and infection. Clinical trials square measure studies of experimental carcinoma treatments. Adult central system growth could be a illness during which abnormal cells kind within the tissues of the brain and/or funiculus. A growth that starts in another a part of the body and spreads to the brain is termed a pathologic process tumor. There are different types of brain and spinal cord tumours such as Astrocytic Tumors, Oligodendroglial Tumors, Mixed Gliomas, Ependymal Tumors, Medulloblastomas, Pineal Parenchymal Tumors, Meningeal Tumors, Germ Cell Tumors, Cranio pharyngioma. Advances in Immuno-oncology have given oncologists and their patient’s reason to be encouraged—the launch of immune stop inhibitors and development of alternative therapy assets for the treatment of many difficult-to-treat diseases, as well as pathologic process skin cancer and non-small cell carcinoma, represents nice progress.

 

  • Track 1-1Immunotherapy categories
  • Track 1-2Genetic pre-testing for therapeutic significance

A major focus of recent studies in cancer medicine is that the immune microenvironment.Multiple cells and molecular interactions inside the expansion microenvironment inhibit malignant tumor immune responses.These cells embody restrictive T cells and myeloid-derived suppressor cells that accumulate in tumors. Each cell kinds suppress cytotoxic T-cell responses that threaten tumors with destruction.Tumor medicine has emerged as a certain discipline relatively recently, and entirely upon the idea that just about all adult tumors arise inside the setting of chronic inflammation, tumor-associated antigens sq.measure immunogenic, and immune responses to element area unit detectable in most tumor-bearing hosts. Though rare, spontaneous cancer regression happens in humans, e.g., in patients with carcinoma and nephritic cancer, and accommodative and innate immune responses can eliminate abnormal cells.

 

  • Track 2-1Cancer Immunology & Immunotherapy
  • Track 2-2Cancer therapeutic resistance
  • Track 2-3Antitumor Effector Cells and Regulation of Tumor Immunity
  • Track 2-4 Pathobiology of Immune System Malignancies

Immuno-oncology’s challenge is to orchestrate a biomarker program in an exceedingly extremely competitive drug development landscape knowing that before having vital clinical expertise, the program is unlikely to yield the kinds of binary measurements wont to outline and choose a patient population for a targeted medical care.

 

  • Track 3-1Tumor-infiltrating immune cells
  • Track 3-2 Immune cell populations / phenotypes
  • Track 3-3 Cytokine profiles
  • Track 3-4Tumor mutation burden / genomic mutation profiling
  • Track 3-5Gene expression signatures

While cancer therapy has created a large leap within the past 5 years, the bulk of therapies at advanced stages of development square measure clustered in a very similar target house. The enlarged investment in immuno-oncology has created associate degree imperative chance to find and populate new target areas that either gift new categories of immunotherapies or is utilized in Combination with existing  products.

  • Track 4-1Emerging immunomodulatory targets
  • Track 4-2Checkpoint inhibitors (PD-1/PD-L1, CTLA-4, TIM3, LAG3)
  • Track 4-3Targeting agonist receptors (OX40, 4-1BB, GITR, CD27, ICOS, GITR)
  • Track 4-4Targeting tumor-associated macrophages (TAM), myeloid-derived suppressor cells (MDSC) and regulatory T cells (Tregs)
  • Track 4-5Targeting the STING pathway
  • Track 4-6Targeting CD96 and TIGIT for cancer immunotherapy
  • Track 4-7Targeting the stroma, tumor micro environment
  • Track 4-8Targeting innate immunity
  • Track 4-9Rational combination Immuno therapy

The tumor microenvironment (TME) is the cellular environment in which the tumor exists, including surrounding blood vessels, immune cells, fibroblasts, bone marrow-derived inflammatory cells, lymphocytes, signaling molecules and the extracellular matrix (ECM).

  • Track 5-1Targeting myloma with Microenvinorment
  • Track 5-2Heterogeneity of the TME
  • Track 5-3Next generation TME studies

Cancer immunotherapy (sometimes called immuno-oncology) is the artificial stimulation of the immune system to treat cancer, improving on the system's natural ability to fight cancer. It is an application of the fundamental research of cancer immunology and a growing subspecialty of oncology. It exploits the fact that cancer cells often have tumor antigens, molecules on their surface that can be detected by the antibody proteins of the immune system, binding to them. The tumor antigens are often proteins or other macromolecules (e.g. carbohydrates). Normal antibodies bind to external pathogens, but the modified immunotherapy antibodies bind to the tumor antigens marking and identifying the cancer cells for the immune system to inhibit or kill.

 

  • Track 6-1Genomics In Cancer Immunotherapy
  • Track 6-2 Latest Immunotherapy Clinical Trials
  • Track 6-3Immunotherapy treatment & side effects

Cancer treatments are reworked with recent advances in cancer therapy. As monotherapies, these agents have incontestible clinical activity across several tumour sorts. Further advances within the effectiveness of cancer immunotherapies would require targeting growth reaction at multiple levels, which can be accomplished through combination approaches. This review discusses this landscape of cancer therapy, mixtures in clinical development, methods for dose choice and trial style, and clinical materia medica and restrictive issue.

  • Track 7-1Oncolytic Virus Immunotherapy
  • Track 7-2Monoclonal antibodies and tumor-agnostic therapies
  • Track 7-3Vaccines Targeting Shared Antigens
  • Track 7-4Vaccines Targeting Neoantigens
  • Track 7-5Immune Checkpoint Inhibitors therapy
  • Track 7-6Targeted therapy and checkpoint immunotherapy combinations

Although abundant progress has been created within the last decade(s) toward development of effective cancer vaccines, there are still necessary obstacles to therapeutic successes. New generations of cancer vaccines can get pleasure from a mixture adjuvant approach that targets multiple branches of the reaction. Some of the different types of cancer vaccines like Traditional vaccines, Cancer Prophylactic (or) prevention vaccines like HPV vaccine, Hepatitis B vaccine; Cancer Therapeutic (or)treatment vaccines like Autologous cancer vaccines, Allogenic cancer vaccines, Protein or Peptide Cancer Vaccines, Antigen vaccines, Whole cell vaccines , Dendritic cell vaccines, DNA vaccines, Anti idiotype vaccines, Viral-based vaccines; Cancer vaccine therapy combined with other treatment modalities, Limitation of Cancer Treatment Vaccines.

 

  • Track 8-1Traditional vaccines
  • Track 8-2Cancer Prophylactic (or) Prevention vaccines
  • Track 8-3Cancer Therapeutic (or) Treatment vaccines
  • Track 8-4Cancer vaccine therapy combined with other treatment modalities
  • Track 8-5Limitation of Cancer Treatment Vaccines

Cell medical care is outlined because the administration of living whole cells for the patient for the treatment of a unwellness. The origin of the cells may be from a similar individual (autologous source) or from another individual (allogeneic source).Cells may be derived from stem cells, like bone marrow or iatrogenic pluripotent stem cells (iPSCs), reprogrammed from skin fibroblasts or adipocytes. Stem cells area unit applied within the context of bone marrow transplantation directly. Other methods involve the applying of a lot of or less mature cells, differentiated in vitro (in a dish) from stem cells.

 

  • Track 9-1 Stem Cell Therapy
  • Track 9-2Chimeric antigen receptor (CAR) T-cell therapy
  • Track 9-3Adaptive Cell Therapy (ACT)
  • Track 9-4Dendritic Cell Therapy
  • Track 9-5Tumor-infiltrating lymphocytes and interleukin-2 (IL-2)

Cancer-A word that fills people with dread. A powerful, devastating word that has destroyed so many lives of cancer victims, their families and loved ones. A word that scientists and doctors are actively and fervently working towards making just a memory. Every year there are new breakthroughs in oncology research and cancer treatments. Unfortunately a lot of these experimental treatments take years to develop and to run them through the required clinical trials, and they still don’t always pan out in the end.

 

  • Track 10-1Gene Therapy
  • Track 10-2Radiation Therapies
  • Track 10-3Hyperthermia Therapy
  • Track 10-4Non - Invasive Cancer Treatments
  • Track 10-5Gene Therapy
  • Track 10-6Immunotherapy
  • Track 10-7Immunotherapeutic Vaccines
  • Track 10-8Drug Therapies
  • Track 10-9Adoptive Cell Transfer Therapies
  • Track 10-10Combination Opdivo and Yervoy
  • Track 10-11Bacterial Therapies and Virotherapy

Drug discovery and development together are the complete process of identifying a new drug and bringing it to market. Discovery may involve screening of chemical libraries, identification of the active ingredient from a natural remedy or design resulting from an understanding of the target. Development includes studies on microorganisms and animals, clinical trials and ultimately regulatory approval.

 

  • Track 11-1Approaches in Anticancer Drug Therapy
  • Track 11-2Drug Development Paradigms for molecularly Targeted Agents
  • Track 11-3Current Drugs in Immunotherapy
  • Track 11-4Traditional Medicines and Herbal Therapy
  • Track 11-5Drug Chemistry and Toxicology
  • Track 11-6Novel Drug Delivery Systems
  • Track 11-7Nuclear Pharmacy
  • Track 11-8Nanotechnology in Drug discovery
  • Track 11-9Clinical Trails and Dosage Studies

Precision medicine is an approach to patient care that allows doctors to select treatments that are most likely to help patients based on a genetic understanding of their disease. This may also be called personalized medicine. According to the Precision Medicine Initiative, precision medicine is "an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person." This approach will allow doctors and researchers to predict more accurately which treatment and prevention strategies for a particular disease will work in which groups of people. Pharmacogenomics is part of precision medicine. Although genomic testing is still a relatively new development in drug treatment, this field is rapidly expanding. Pharmacogenomics is the study of how a person's unique genetic makeup (genome) influences his or her response to medications.

 

The demand for predictive and robust preclinical models and approaches to minimize translational failures in immuno-oncology is at an all-time high. The need for leveraging phenotypic features of models, for early identification of predictive biomarkers, for rational design of combination therapies, and for researching the cancer-immune cell interactions add to the complexity of translational research in immune-oncology.

 

The unique side effects of checkpoint inhibitors are uniformly termed as immune-related adverse events (irAEs). These include a range of mainly dermatologic, gastrointestinal (GI), endocrine and hepatic toxicities, as well as several other less common inflammatory events. All these adverse events have variable times of onset, they have an autoimmune etiology and they need careful monitoring, follow-up and management. With appropriate and timely treatment, these toxicities are usually reversible, but they can become severe and even life-threatening if they are not recognized early enough. These checkpoint inhibitor side effects are reviewed here and their management is presented based on clinical experience and published guidelines, algorithms and recommendations, which refer mainly to the knowledge obtained from the use of ipilimumab.

 

Personalized medicine uses traditional, as well as emerging concepts of the genetic and environmental basis of disease to individualize prevention, diagnosis and treatment. Personalized genomics plays a vital, but not exclusive role in this evolving model of personalized medicine. The distinctions between genetic and genomic medicine are more quantitative than qualitative. Personalized genomics builds on principles established by the integration of genetics into medical practice. Principles shared by genetic and genomic aspects of medicine, include the use of variants as markers for diagnosis, prognosis, prevention, as well as targets for treatment, the use of clinically validated variants that may not be functionally characterized, the segregation of these variants in non-Mendelian as well as Mendelian patterns, the role of gene–environment interactions, the dependence on evidence for clinical utility, the critical translational role of behavioral science, and common ethical considerations. During the current period of transition from investigation to practice, consumers should be protected from harms of premature translation of research findings, while encouraging the innovative and cost-effective application of those genomic discoveries that improve personalized medical care.

 

  • Track 16-1Coverage and reimbursement issues in Cancer biomarkers
  • Track 16-2Policy issues in the development of Personalized Medicine
  • Track 16-3Biomarkers for Molecularly Targeted Cancer Therapies
  • Track 16-4Ethical, legal and social implications (ELSI) of Cancer Biomarkers